Company Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 18:13:44 13/03/2026 GMT			5-day change	1st Jan Change
96.14 ^USD	+1.13%		-2.39%	+20.59%

03-04	Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing	MT
03-03	Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM

Business description: Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Companyâ€™s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Companyâ€™s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.

Number of employees: 883

Sales by Activity: Revolution Medicines, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
Biotechnology	29.39M	35.38M	11.58M	-	-

See all business segments

Geographical breakdown of sales: Revolution Medicines, Inc.

Fiscal Period: December	2021 (USD)	2022 (USD)	2023 (USD)	2024 (USD)	2025 (USD)
United States	29.39M	35.38M	11.58M	-	-

See all geographic segments

Executive Committee: Revolution Medicines, Inc.

Manager	Title	Age	Since
Mark Goldsmith CEO	Chief Executive Officer	64	31/10/2014
Jack Anders DFI	Director of Finance/CFO	49	30/09/2018
Wei Lin CTO	Chief Tech/Sci/R&D Officer	64	31/03/2023
Wally Reiher CTO	Chief Tech/Sci/R&D Officer	-	31/08/2020
Steve Kelsey CTO	Chief Tech/Sci/R&D Officer	65	28/02/2017

See REVOLUTION MEDICINES, INC. governance

Composition of the Board of Directors: Revolution Medicines, Inc.

Director	Title	Age	Since
Mark Goldsmith CHM	Chairman	64	31/12/2019
Elizabeth Anderson BRD	Director/Board Member	68	28/02/2015
Alexis Borisy BRD	Director/Board Member	54	31/10/2014
Thilo Schroeder BRD	Director/Board Member	44	28/02/2018
Flavia Borellini BRD	Director/Board Member	64	21/06/2021
Sushil Patel BRD	Director/Board Member	55	15/06/2022
Lorence Kim BRD	Director/Board Member	52	11/07/2022
Sandra Horning BRD	Director/Board Member	77	08/11/2023
Franklin Clyburn BRD	Director/Board Member	61	04/08/2024

Composition of the Board of Directors

Shareholders: Revolution Medicines, Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 8.437 %	16,719,886	8.437 %	1 706 M $
Farallon Capital Management LLC 7.359 %	14,582,796	7.359 %	1 488 M $
Janus Henderson Investors US LLC 6.208 %	12,303,502	6.208 %	1 255 M $
Baker Bros. Advisors LP 4.771 %	9,455,357	4.771 %	965 M $
Fidelity Management & Research Co. LLC 4.333 %	8,586,477	4.333 %	876 M $

Name	Equities	%	Valuation
T Rowe Price Associates, Inc. (13F Subfiler) -	4,000,651	-	9 M $
LMR Partners LLP -	3,151,705	-	7 M $
D.E. Shaw & Co., Inc. -	1,454,895	-	3 M $
Aristeia Capital LLC -	624,935	-	1 M $
City National Rochdale LLC -	507,997	-	1 M $

List of REVOLUTION MEDICINES, INC. shareholders

Company details: Revolution Medicines, Inc.

Revolution Medicines, Inc.

700 Saginaw Drive

94063, Redwood City

+650 481 6801

http://www.revmed.com

address Revolution Medicines, Inc.(RVMD)

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
REVOLUTION MEDICINES, INC.	+1.13%	-2.39%	+146.09%	+325.38%	18.84B
LONZA GROUP AG	-0.72%	-4.60%	-11.02%	-8.56%	43.38B
BEONE MEDICINES AG	-0.52%	-5.77%	+11.46%	+27.68%	31.64B
CELLTRION, INC.	-0.24%	-2.84%	+14.35%	+45.06%	30.26B
IQVIA HOLDINGS INC.	+1.45%	-5.57%	-9.18%	-16.83%	27.35B
ASCENDIS PHARMA A/S	-1.29%	-6.19%	+48.22%	+109.72%	14.06B
MEDPACE HOLDINGS, INC.	+0.89%	-4.75%	+40.99%	+157.15%	12.6B
EUROFINS SCIENTIFIC SE	-0.29%	-4.80%	+21.98%	-2.54%	12.52B
IONIS PHARMACEUTICALS, INC.	-1.77%	-3.93%	+116.20%	+111.82%	11.95B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-2.85%	-0.64%	+6,156.74%	+3,226.64%	11.87B
Average	-0.41%	-4.07%	+653.58%	+397.55%	21.45B
Weighted average by Cap.	-0.28%	-4.14%	+367.18%	+236.21%